Form 8-K - Current report:
SEC Accession No. 0001104659-25-063028
Filing Date
2025-06-26
Accepted
2025-06-26 16:01:51
Documents
13
Period of Report
2025-06-26
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2519221d1_8k.htm   iXBRL 8-K 39317
5 GRAPHIC tm2519221d1_8kimg002.jpg GRAPHIC 106911
  Complete submission text file 0001104659-25-063028.txt   485994

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ewtx-20250626.xsd EX-101.SCH 3020
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ewtx-20250626_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ewtx-20250626_pre.xml EX-101.PRE 22362
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2519221d1_8k_htm.xml XML 3567
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40236 | Film No.: 251080307
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)